{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: EQ-5D-5L and MLHFQ predict all-cause mortality in ATTR-CM, independent of biomarkers."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [ROADMAP]**: Integrate KCCQ with CV outcomes in trials to meet FDAâ€™s evolving PRO-driven approval standards."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: FDA increasingly prioritizes PROs like KCCQ for approval, shifting from traditional CV endpoints."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Varying baseline characteristics across trials may skew PRO comparisons, complicating real-world applicability."
    }
  ],
  "model": "qwen3:latest"
}